Brief description of study

This is a phase 2 trial of selumetinib (AZD6244 hydrogen sulfate) in children with recurrent or refractory solid tumors, CNS tumors, non-Hodgkin lymphomas and histiocytic disorders harboring specific activating mutations that result in pathologic activation of the MAPK pathway.
Patients will receive selumetinib (AZD6244 hydrogen sulfate) for 28-day cycles at the MTD and recommended Phase 2 dose (RP2D) of 25 mg/m2/dose BID.
The primary aim of this trial will be to establish the objective response rate to selumetinib (AZD6244 hydrogen sulfate). While there will not be multiple pre-determined mutation-based cohorts, responses will be analyzed retrospectively with respect to specific MAPK pathway activating mutations.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.